Dendreon Corp fka DNDNQ

[DewDiligence]

There is no hoax or conspiracy—DNDN thinks Provenge works and hopes the 9902b trial will be successful. However, they realize they will have a much easier time raising capital after a failed interim analysis if the final analysis is due 9-12 months later than if it were due 24 months later.

Naturally, DNDN management did not want to admit to investors that the impetus for the revised SPA was primarily financial, so they told investors the rationale for the change was increased confidence in the outcome. They knew that people like ocyan would accept the company’s explanation, hook, line and sinker, as they always do.